Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Advanced Malignant Solid Neoplasm 1

Interventions

Cisplatin 27pembrolizumab 21Brachytherapy 16Radiotherapy 14Carboplatin 10Radiation 8Paclitaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Topotecan 6fludarabine 5atezolizumab 5Magnetic Resonance Spectroscopy 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Nivolumab 4Gemcitabine 4tremelimumab 3temsirolimus 3human papillomavirus vaccine, L1 type 16, 18 3aldesleukin 3Radiotherapy, Intensity-Modulated 3Papillomavirus Vaccines 3Ipilimumab 3Interleukin-2 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Docetaxel 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uterine Cervical Neoplasms × Pharmacogenomic Variants × Clear all
NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

M.D. Anderson Cancer Center

Phase 1 Completed
26 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡